Glycoprotein-secreting pituitary adenomas

Mary Samuels, E. Chester Ridgway

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

In the past, pituitary tumours that produce one or more of the glycoproteins (TSH, LH, FSH and α subunit) were thought to be rare. However, using modern immunocytochemical and molecular biology techniques, these tumours are being recognized with increasing frequency. Many of these tumours produce glycoprotein α and β subunits in addition to intact glycoproteins. Hormone production is often low compared with tumour size, and serum hormone levels may not be elevated in these patients. Tumours that produce the gonadotrophins (LH or FSH) or α subunit account for the majority of clinically non-functioning pituitary adenomas. They do not cause a specific clinical syndrome, and usually present with symptoms of a large mass lesion and/or hypopituitarism. Optimal treatment of these tumours is often difficult. The initial approach is usually transsphenoidal surgery, followed by radiation therapy if there are symptoms due to residual tumour. Medical therapy of gonadotrophin and α subunit tumours may include the use of dopamine agonists or somatostatin analogues, although neither has been shown to consistently decrease tumour size. Preliminary trials with experimental GnRH antagonists suggest that these agents may be useful as adjuvant therapy of gonadotrophin tumours. Tumours that produce TSH are rare. Patients present with hyperthyroidism, which is often misdiagnosed as Graves' disease, as well as with symptoms of a pituitary mass lesion. Almost all TSH tumours secrete excess amounts of free α subunit. Optimal treatment of these tumours includes transsphenoidal surgery, followed by radiation therapy for residual tumour. The somatostatin analogue octreotide is effective in reducing excess TSH secretion from these tumours, and causes a reduction in tumour volume in a significant minority of patients.

Original languageEnglish (US)
Pages (from-to)337-358
Number of pages22
JournalBailliere's Clinical Endocrinology and Metabolism
Volume9
Issue number2
DOIs
StatePublished - 1995
Externally publishedYes

Fingerprint

Pituitary Neoplasms
Tumors
Glycoproteins
Neoplasms
Gonadotropins
Residual Neoplasm
Somatostatin
Radiotherapy
Hormones
Surgery
Hypopituitarism
Octreotide
Graves Disease
Dopamine Agonists
Hyperthyroidism
Therapeutics
Tumor Burden
Diagnostic Errors
Gonadotropin-Releasing Hormone
Molecular biology

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology

Cite this

Glycoprotein-secreting pituitary adenomas. / Samuels, Mary; Ridgway, E. Chester.

In: Bailliere's Clinical Endocrinology and Metabolism, Vol. 9, No. 2, 1995, p. 337-358.

Research output: Contribution to journalArticle

@article{8e42b058eb524d4a80ef064a9a7d63e3,
title = "Glycoprotein-secreting pituitary adenomas",
abstract = "In the past, pituitary tumours that produce one or more of the glycoproteins (TSH, LH, FSH and α subunit) were thought to be rare. However, using modern immunocytochemical and molecular biology techniques, these tumours are being recognized with increasing frequency. Many of these tumours produce glycoprotein α and β subunits in addition to intact glycoproteins. Hormone production is often low compared with tumour size, and serum hormone levels may not be elevated in these patients. Tumours that produce the gonadotrophins (LH or FSH) or α subunit account for the majority of clinically non-functioning pituitary adenomas. They do not cause a specific clinical syndrome, and usually present with symptoms of a large mass lesion and/or hypopituitarism. Optimal treatment of these tumours is often difficult. The initial approach is usually transsphenoidal surgery, followed by radiation therapy if there are symptoms due to residual tumour. Medical therapy of gonadotrophin and α subunit tumours may include the use of dopamine agonists or somatostatin analogues, although neither has been shown to consistently decrease tumour size. Preliminary trials with experimental GnRH antagonists suggest that these agents may be useful as adjuvant therapy of gonadotrophin tumours. Tumours that produce TSH are rare. Patients present with hyperthyroidism, which is often misdiagnosed as Graves' disease, as well as with symptoms of a pituitary mass lesion. Almost all TSH tumours secrete excess amounts of free α subunit. Optimal treatment of these tumours includes transsphenoidal surgery, followed by radiation therapy for residual tumour. The somatostatin analogue octreotide is effective in reducing excess TSH secretion from these tumours, and causes a reduction in tumour volume in a significant minority of patients.",
author = "Mary Samuels and Ridgway, {E. Chester}",
year = "1995",
doi = "10.1016/S0950-351X(95)80370-X",
language = "English (US)",
volume = "9",
pages = "337--358",
journal = "Bailliere's Clinical Endocrinology and Metabolism",
issn = "0950-351X",
publisher = "Bailliere Tindall Ltd",
number = "2",

}

TY - JOUR

T1 - Glycoprotein-secreting pituitary adenomas

AU - Samuels, Mary

AU - Ridgway, E. Chester

PY - 1995

Y1 - 1995

N2 - In the past, pituitary tumours that produce one or more of the glycoproteins (TSH, LH, FSH and α subunit) were thought to be rare. However, using modern immunocytochemical and molecular biology techniques, these tumours are being recognized with increasing frequency. Many of these tumours produce glycoprotein α and β subunits in addition to intact glycoproteins. Hormone production is often low compared with tumour size, and serum hormone levels may not be elevated in these patients. Tumours that produce the gonadotrophins (LH or FSH) or α subunit account for the majority of clinically non-functioning pituitary adenomas. They do not cause a specific clinical syndrome, and usually present with symptoms of a large mass lesion and/or hypopituitarism. Optimal treatment of these tumours is often difficult. The initial approach is usually transsphenoidal surgery, followed by radiation therapy if there are symptoms due to residual tumour. Medical therapy of gonadotrophin and α subunit tumours may include the use of dopamine agonists or somatostatin analogues, although neither has been shown to consistently decrease tumour size. Preliminary trials with experimental GnRH antagonists suggest that these agents may be useful as adjuvant therapy of gonadotrophin tumours. Tumours that produce TSH are rare. Patients present with hyperthyroidism, which is often misdiagnosed as Graves' disease, as well as with symptoms of a pituitary mass lesion. Almost all TSH tumours secrete excess amounts of free α subunit. Optimal treatment of these tumours includes transsphenoidal surgery, followed by radiation therapy for residual tumour. The somatostatin analogue octreotide is effective in reducing excess TSH secretion from these tumours, and causes a reduction in tumour volume in a significant minority of patients.

AB - In the past, pituitary tumours that produce one or more of the glycoproteins (TSH, LH, FSH and α subunit) were thought to be rare. However, using modern immunocytochemical and molecular biology techniques, these tumours are being recognized with increasing frequency. Many of these tumours produce glycoprotein α and β subunits in addition to intact glycoproteins. Hormone production is often low compared with tumour size, and serum hormone levels may not be elevated in these patients. Tumours that produce the gonadotrophins (LH or FSH) or α subunit account for the majority of clinically non-functioning pituitary adenomas. They do not cause a specific clinical syndrome, and usually present with symptoms of a large mass lesion and/or hypopituitarism. Optimal treatment of these tumours is often difficult. The initial approach is usually transsphenoidal surgery, followed by radiation therapy if there are symptoms due to residual tumour. Medical therapy of gonadotrophin and α subunit tumours may include the use of dopamine agonists or somatostatin analogues, although neither has been shown to consistently decrease tumour size. Preliminary trials with experimental GnRH antagonists suggest that these agents may be useful as adjuvant therapy of gonadotrophin tumours. Tumours that produce TSH are rare. Patients present with hyperthyroidism, which is often misdiagnosed as Graves' disease, as well as with symptoms of a pituitary mass lesion. Almost all TSH tumours secrete excess amounts of free α subunit. Optimal treatment of these tumours includes transsphenoidal surgery, followed by radiation therapy for residual tumour. The somatostatin analogue octreotide is effective in reducing excess TSH secretion from these tumours, and causes a reduction in tumour volume in a significant minority of patients.

UR - http://www.scopus.com/inward/record.url?scp=0029036238&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029036238&partnerID=8YFLogxK

U2 - 10.1016/S0950-351X(95)80370-X

DO - 10.1016/S0950-351X(95)80370-X

M3 - Article

C2 - 7625988

AN - SCOPUS:0029036238

VL - 9

SP - 337

EP - 358

JO - Bailliere's Clinical Endocrinology and Metabolism

JF - Bailliere's Clinical Endocrinology and Metabolism

SN - 0950-351X

IS - 2

ER -